文献速递浆细胞疾病

多发性骨髓瘤中获得性del(17p)的影响

Impact of acquired del(17p) in multiple myeloma.
PubMed 文献 · Blood Adv · 2019-01-01

该研究比较了76例诊断时del(17p)阴性但后续获得del(17p)的多发性骨髓瘤患者与152例未获得del(17p)的对照患者。获得性del(17p)患者从诊断起的中位无进展生存期(30.1 vs 23.0个月;获得del(17p)是总生存期缩短的重要分子事件。

要点

  • 诊断时高LDH水平及t(4;14)或任何高危易位可预测del(17p)的获得。

核心结论

  • 获得性del(17p)是多发性骨髓瘤中与总生存期缩短相关的重要分子事件。
  • 某些基线因素可能预测del(17p)的获得,需在前瞻性数据集中验证。

研究设计与样本

  • 比较76例诊断时del(17p)阴性但后续获得del(17p)的多发性骨髓瘤患者与152例未获得del(17p)的对照患者。
  • 患者获得del(17p)的中位时间为诊断后35.6个月(范围4.6-116.1个月),中位治疗线数为2线(范围1-10线)。

主要发现

  • 检测到del(17p)后,中位PFS为5.4个月,中位OS为18.1个月。
  • 诊断时高乳酸脱氢酶水平(OR 3.69;95%CI 1.11-12.24)和t(4;14)(OR 2.66;95%CI 1.09-6.48)或任何高危易位(OR 2.23;95%CI 1.00-4.95)预测del(17p)的获得。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The high-risk abnormality del(17p) can be detected by fluorescence in situ hybridization on malignant plasma cells (PCs) and has an adverse prognostic impact in patients with multiple myeloma (MM). Patients with del(17p) have reduced overall survival (OS). Patients who acquire del(17p) later during the disease course are not well described. The disease characteristics at diagnosis predicting for acquired del(17p) and its overall impact on patient survival is not known. We compared 76 patients with MM who were negative for del(17p) at diagnosis and acquired it later with 152 control MM patients who did not acquire del(17p) at a comparable time point. Patients acquired del(17p) at a median of 35.6 months (range, 4.6-116.1 months) from diagnosis of MM after a median of 2 lines of therapy (range, 1-10 lines of therapy). When compared with controls, patients with acquired del(17p) had shorter median progression-free survival (PFS) (30.1 vs 23.0 months; P = .032) and OS (106.1 vs 68.2 months; P < .001) from diagnosis. After the detection of del(17p), the median PFS was 5.4 months and the median OS was 18.1 months. High lactate dehydrogenase level (odds ratio [OR], 3.69; 95% confidence interval [CI], 1.11-12.24) and presence of t(4;14) (OR, 2.66; 95% CI, 1.09-6.48) or any high-risk translocation (OR, 2.23; 95% CI, 1.00-4.95) at diagnosis predicted acquisition of del(17p). High PC proliferative rate predicted shorter OS from detection of del(17p) (hazard ratio, 2.28; 95% CI, 1.31-3.96; P = .004). Our study shows that acquisition of del(17p) is an important molecular event associated with reduction in OS in MM. Certain baseline factors may predict acquisition of del(17p). This needs validation in prospective data sets.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Lakshman A, Painuly U, Rajkumar SV, et al. Impact of acquired del(17p) in multiple myeloma. Blood Adv. 2019. PMID: 31248884. doi:10.1182/bloodadvances.2018028530

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。